Provided by Tiger Trade Technology Pte. Ltd.

Armata Pharmaceuticals, Inc.

3.31
-0.3600-9.81%
Post-market: 3.310.00000.00%19:30 EDT
Volume:76.46K
Turnover:263.77K
Market Cap:123.07M
PE:-0.63
High:3.78
Open:3.67
Low:3.28
Close:3.67
52wk High:16.34
52wk Low:2.94
Shares:37.18M
Float Shares:11.88M
Volume Ratio:0.70
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.2744
EPS(LYR):-4.8000
ROE:-3439.35%
ROA:-25.83%
PB:-0.53
PE(LYR):-0.69

Loading ...

Armata Wins FDA Agreement on Pediatric Study Plan for Ap-sa02 in Complicated S. Aureus Bacteremia

Reuters
·
Jul 13

Armata Pharmaceuticals - Adult Phase 3 Study for Ap-sa02 Expected to Initiate in Second Half of 2026

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for Ap-sa02 for the Treatment of Complicated Staphylococcus Aureus Bacteremia

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Defers Pediatric Studies for Ap-sa02 Until Adult Phase 3 Data Generated

THOMSON REUTERS
·
Jul 13

Armata Pharmaceuticals - FDA Agreement Establishes Regulatory Framework for Ap-sa02 in Pediatric SAB

THOMSON REUTERS
·
Jul 13

Armata Pharma Amends 8-K to Disclose Director Daniel Gilmer Committee Assignment

Reuters
·
Jun 25

Sector Update: Healthcare Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Jun 23

Armata Pharmaceuticals Shares Rise on Additional $2.5M Government Grant

Dow Jones
·
Jun 23

Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 program

Reuters
·
Jun 23

Armata Pharmaceuticals Receives $2.5 Million of Additional Non-Dilutive Award Funding From the U.S. Department of Defense to Support AP-Sa02

THOMSON REUTERS
·
Jun 23

Armata Pharmaceuticals shareholders elect seven directors at annual meeting

Reuters
·
Jun 17

BRIEF-Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update

Reuters
·
May 14

Armata Pharmaceuticals Q1 EPS $(3.16) Misses $(0.38) Estimate, Sales $789.000K Up From $491.000K YoY

Benzinga Earnings
·
May 14

Armata Q1 FY26 net loss widens to $115.35 million

Reuters
·
May 14

Armata Pharmaceuticals Inc - Q1 Net Loss $115.3 Mln or $3.16 Loss per Share VS $6.5 Mln or $0.18 Loss Year Ago

THOMSON REUTERS
·
May 14

Armata Pharmaceuticals Inc - Enters Secured Credit Agreement With Innoviva for $25 Mln Maturing in 2029

THOMSON REUTERS
·
May 14

Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-Sa02

THOMSON REUTERS
·
May 07

Armata Pharmaceuticals Inc - to Initiate Phase 3 Study of AP-Sa02 in H2 2026

THOMSON REUTERS
·
May 07

Armata reports cryo-EM study maps structure of Pseudomonas phage P7-1

Reuters
·
May 04

Armata Pharma director Daniel Gilmer files initial beneficial ownership statement

Reuters
·
Apr 29